CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM – QNT Press Release


Enrollment progressing toward interim analysis, planned when 30-50% of subjects reach 6 months in study

HOUSTON, Nov. 2, 2022 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the first patient in Europe has been enrolled and dosed in France in the Company’s ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

The Company has opened 29 clinical trial sites of the 68 sites selected across the US, Italy, France, Spainand Switzerland. A pre-planned, non-binding utility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.

“Our team has worked tirelessly to expand the presence of our clinical trial for Berubicin on a global scale. To have enrolled and dosed our first patient in France shortly after the opening the site is a noteworthy accomplishment and a testament to our team’s dedication to drive the program forward. I am pleased with the progress made and remain committed to building on this momentum. We expect to enroll and dose additional patients across our clinical trial sites in Europe and advance toward the much-anticipated inflection…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center